Safety, immunogenicity, and kinetics of the immune response to a single dose of virosome-formulated hepatitis A vaccine in Thais.
The safety and immunogenicity of a single dose of virosome-formulated hepatitis A vaccine was evaluated in healthy seronegative Thai volunteers. Immunization elicited primarily mild transient reactions which did not interfere with normal activities. All subjects possessed > 20 mIU of anti-hepatitis A virus antibody per ml of serum one month after immunization. Such a prolonged rise in antibody titre is characteristic of virosome-formulated vaccines. Protective titres (> 20 mIU ml-1) were maintained by all subjects over the one-year observation period.
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis; D000956:Antigens, Viral / Q000276:immunology*; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006506:Hepatitis A / Q000276:immunology / Q000517:prevention & control; D006507:Hepatovirus / Q000276:immunology*; D006801:Humans; D008297:Male; D013785:Thailand; D014761:Viral Hepatitis Vaccines / Q000009:adverse effects* / Q000276:immunology* / Q000493:pharmacokinetics
D000914:Antibodies, Viral; D000956:Antigens, Viral; D014761:Viral Hepatitis Vaccines